1.中山大学中山医学院生物化学与分子生物学教研室,广东 广州 510080
2.广州市妇女儿童医疗中心,广东 广州 510623
3.广东省基因操作和生物大分子产物工程技术研究中心,广东 广州 510080
杨洋,硕士生,研究方向:神经母细胞瘤发生发展机制研究,E-mail: yang310917@163.com
收稿:2021-08-25,
纸质出版:2022-01-20
移动端阅览
杨洋,杨风雨,张晓燕等.DNA去甲基化酶TET在神经母细胞瘤患者中表达及意义[J].中山大学学报(医学科学版),2022,43(01):43-50.
YANG Yang,YANG Feng-yu,ZHANG Xiao-yan,et al.Expression and Clinical Significance of DNA Demethylase TET in the Tissues in Patients with Neuroblastoma[J].Journal of Sun Yat-sen University(Medical Sciences),2022,43(01):43-50.
杨洋,杨风雨,张晓燕等.DNA去甲基化酶TET在神经母细胞瘤患者中表达及意义[J].中山大学学报(医学科学版),2022,43(01):43-50. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2022.0106.
YANG Yang,YANG Feng-yu,ZHANG Xiao-yan,et al.Expression and Clinical Significance of DNA Demethylase TET in the Tissues in Patients with Neuroblastoma[J].Journal of Sun Yat-sen University(Medical Sciences),2022,43(01):43-50. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2022.0106.
目的
2
检测神经母细胞瘤(NB)患者组织中DNA去甲基化酶十一易位蛋白(TET) TET1、TET2、TET3的表达水平,探讨TET在神经母细胞瘤患者组织中的表达及临床意义。
方法
2
神经母细胞瘤患者组织标本46例,用免疫组织化学法(IHC)检测TET1、TET2、TET3在NB患者组织中的表达水平;使用Target数据库中的临床数据分析TET1、TET2、TET3的表达与NB患者预后的关系并进行批量相关性分析。用SPSS 25.0统计学软件进行分析,GraphPad Prism 8软件作图。
结果
2
①免疫组化结果显示,在不同级别有丝分裂-核碎裂指数(MKI)的NB患者组织中,TET3的表达存在差异且具有统计学意义(
P
=0.037)。TET3的表达水平在不同肿瘤细胞分化程度的各组间存在统计学差异(
P
=0.041),TET3高表达与NB患者预后良好呈正相关(
P
=0.020)。TET1表达与肾上腺素能受体2(β2-AR)表达呈正相关(
r
=0.347,
P
=0.023)。②生物信息学分析结果表明,TET3 mRNA表达水平与ADNP(神经保护蛋白)、ARID2(染色质重塑因子)等抑癌基因的mRNA表达水平呈正相关,与CD63(四次跨膜蛋白)、JOSD2(去泛素化酶)等癌基因的mRNA表达水平呈负相关;TARGET数据库中TET3 mRNA水平与神经母细胞瘤患者总生存期(OS)和无事件生存期(EFS)呈正相关(
P
=0.024,
P
=0.014)。
结论
2
TET3在NB患者组织中的表达与患者临床特征有一定的关系,且TET3高表达与NB患者预后良好呈正相关,提示TET3在神经母细胞瘤中可能作为肿瘤抑制因子发挥作用,TET3可以作为预测NB患者预后的一个潜在指标,对NB的临床评估有一定的价值。
Objective
2
To detect the expression level of DNA demethylase ten eleven translocation TET1, TET2, TET3 in the tissues of neuroblastoma (NB) patients,and to explore the expression and clinical significance of TET in patients with neuroblastoma.
Methods
2
Immunohistochemistry (IHC) was used to detect the expression levels of TET1, TET2 and TET3 in the tissues of 46 patients with neuroblastoma; clinical data from Target database were used to analyze the relationship between the expression of TET1, TET2, TET3 and prognosis of NB patients, and batch correlation analysis was conducted. SPSS 25.0 statistical software was used for analysis, and GraphPad Prism 8 was used for plotting.
Results
2
①Immunohistochemical results showed that the expression of TET3 in neuroblastoma patients with different levels of mitosis karyorrhexis index (MKI) was significantly different with statistical significance (
P
=0.037). The expression level of TET3 was statistically different among different groups of tumor cell differentiation (
P
=0.041), and high expression of TET3 was positively correlated with good prognosis of patients (
P
=0.020). The expression of TET1 was positively correlated with the expression of β2-AR (
r
=0.347,
P
=0.023). ②Bioinformatics analysis showed that the mRNA expression level of TET3 was positively correlated with the mRNA expression level of tumor suppressor genes such as activity-dependent neuroprotective protein (ADNP, a neuroprotective protein) and AT-rich interactive domain 2 (ARID2, a chromatin remodeling factor), and negatively correlated with the mRNA expression level of oncogenes such as CD63 (fourth transmembrane protein) and Josephin domain-containing protein 2 (JOSD2, deubiquitination enzyme). TARGET database showed that TET3 mRNA level was positively correlated with overall survival (OS) and event-free survival (EFS) of neuroblastoma patients (
P
=0.024,
P
=0.014).
Conclusions
2
The expression of TET3 in NB patients has a certain relationship with the clinical features of neuroblastoma patients, and the high expression of TET3 is positively correlated with the good prognosis of NB patients, suggesting that TET3 may play a role as a tumor suppressive factor in neuroblastoma, and TET3 can be used as a potential indicator to predict the prognosis of NB patients. It has some value in the clinical evaluation of NB.
Zafar A , Wang W , Liu G , et al . Molecular targeting therapies for neuroblastoma: progress and challenges [J]. Med Res Rev , 2021 , 41 ( 2 ): 961 - 1021 .
Park JR , Kreissman SG , London WB , et al . Effect of Tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial [J]. JAMA , 2019 , 8 ( 322 ): 746 - 755 .
Tonini GP , Capasso M . Genetic predisposition and chromosome instability in neuroblastoma [J]. Cancer Metastasis Rev , 2020 , 1 ( 39 ): 275 - 285 .
Wang A , Deng S , Chen X , et al . miR-29a-5p/STAT3 positive feedback loop regulates TETs in colitis-associated colorectal cancer [J]. Inflamm Bowel Dis , 2020 , 4 ( 26 ): 524 - 533 .
Carella A , Tejedor JR , García MG , et al . Epigenetic downregulation of TET3 reduces genome-wide 5hmC levels and promotes glioblastoma tumorigenesis [J]. Int J Cancer , 2020 , 2 ( 146 ): 373 - 387 .
Dong ZR , Ke AW , LI T , et al . CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity [J]. Mol Cancer , 2021 , 20 ( 1 ): 75 .
Bai X , Zhang H , Zhou Y , et al . Ten-eleven translocation 1 promotes malignant progression of cholangiocarcinoma with wild-type isocitrate dehydrogenase 1 [J]. Hepatology , 2021 , 73 ( 5 ): 1747 - 1763 .
Li Z , Lyu C , Ren Y , et al . Role of TET dioxygenases and DNA hydroxymethylation in bisphenols-stimulated proliferation of breast cancer cells [J]. Environ Health Perspect , 2020 , 128 ( 2 ): 27008 .
Deng J , Jiang P , Yang T , et al . Targeting β3-adrenergic receptor signaling inhibits neuroblastoma cell growth via suppressing the mTOR pathway [J]. Biochem Biophys Res Commun , 2019 , 514 ( 1 ): 295 - 300 .
Liu C , Yang Y , Chen C , et al . Environmental eustress modulates β-ARs/CCL2 axis to induce anti-tumor immunity and sensitize immunotherapy against liver cancer in mice [J]. Nat Commun , 2021 , 12 ( 1 ): 5725 .
Qiao G , Chen M , Mohammadpour H , et al . Chronic adrenergic stress contributes to metabolic dysfunction and an exhausted phenotype in T cells in the tumor microenvironment [J]. Cancer Immunol Res , 2021 , 9 ( 6 ): 651 - 664 .
Deng J , Jiang P , Yang T , et al . β2‑adrenergic receptor signaling promotes neuroblastoma cell proliferation by activating autophagy [J]. Oncol Rep , 2019 , 4 ( 42 ): 1295 - 1306 .
Gao J , Ma Y , Fu HL , et al . Non-catalytic roles for TET1 protein negatively regulating neuronal differentiation through srGAP3 in neuroblastoma cells [J]. Protein Cell , 2016 , 5 ( 7 ): 351 - 361 .
Yang X , Zhao T , Feng L , et al . PM(2.5)-induced ADRB2 hypermethylation contributed to cardiac dysfunction through cardiomyocytes apoptosis via PI3K/Akt pathway [J]. Environ Int , 2019 , ( 127 ): 601 - 614 .
Jiang S . Tet2 at the interface between cancer and immunity [J]. Commun Biol , 2020 , 1 ( 3 ): 667 .
Xu YP , Lv L , Liu Y , et al . Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy [J]. J Clin Invest , 2019 , 10 ( 129 ): 4316 - 4331 .
Kim MR , Wu MJ , Zhang Y , et al . TET2 directs mammary luminal cell differentiation and endocrine response [J]. Nat Commun , 2020 , 1 ( 11 ): 4642 .
Zhang T , Zhao Y , Zhao Y , et al . Expression and prognosis analysis of TET family in acute myeloid leukemia [J]. Aging (Albany NY) , 2020 , 6 ( 12 ): 5031 - 5047 .
Sun X , Peng X , Cao Y , et al . ADNP promotes neural differentiation by modulating Wnt/β-catenin signaling [J]. Nat Commun , 2020 , 1 ( 11 ): 2984 .
Fetahu IS and Taschner-Mandl S . Neuroblastoma and the epigenome [J]. Cancer Metastasis Rev , 2021 , 1 ( 40 ): 173 - 189 .
0
浏览量
340
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621
